A randomized, double-blind, placebo-controlled pilot trial of intravenous @entity2399 in XXXX .

@entity1 @entity64 @entity1024 @entity2399 @entity2500 @entity204 @entity1760
BACKGROUND AND PURPOSE: @entity1760 ions act as endogenous vasodilators of the cerebral circulation and act pharmacologically as noncompetitive antagonists of the @entity1024 receptor by virtue of their role as endogenous voltage-sensitive blockers of the ion channel. The preclinical efficacy of @entity1760 has been demonstrated in standard models of @entity64 . METHODS: Sixty @entity1 were randomized to @entity2399 (8 mmol IV over 15 minutes and 65 mmol over 24 hours) or placebo within 12 hours of clinically diagnosed @entity2500 . Pulse, blood pressure, and serum @entity1760 levels were monitored. Primary outcome was @entity204 or significant functional impairment (Barthel Index score < 60) at 3 months. RESULTS: @entity1760 was well tolerated, with no significant adverse effects and no change in blood pressure or pulse rate. Laboratory and electrocardiographic variables did not differ significantly between placebo- and @entity1760 -treated groups. Serum @entity1760 rose from 0.76 mmol/L to 1.42 mmol/L over 24 hours and remained significantly higher than in the placebo group at 48 hours. Thirty percent of @entity1760 -treated and 40% of placebo-treated @entity1 were dead or disabled (Barthel Index score < 60) at 3 months (P = .42). There was a decrease in the number of early deaths in the @entity1760 -treated group (P = .066, log-rank test). CONCLUSIONS: @entity2399 is well tolerated after @entity64 and has no deleterious hemodynamic effects at this dose. Further trials are required to determine efficacy.
